CFRA Research Becomes Exclusive Global Equity Research Provider for Geneva-Based Banque Audi Suisse
Exclusive partnership expands access to global equity research for Bank Audi Suisse team of investment professionals through CFRA’s industry-leading MarketScope Advisor Platform.
CFRA, the world’s leading provider of independent investment research today announced that its global fundamental equity, thematic, and sector research is now available to Banque Audi Suisse investment professionals and relationship managers, exclusively through their MarketScope Advisor platform.
The partnership provides Banque Audi Suisse with real-time access to CFRA’s industry-leading research and analytical tools to help their investment teams stay on top of changes in global markets, make well-informed investment decisions, and deliver value to their affluent client base.
"Our search for a global equity research provider was driven by our commitment to delivering maximum value to our client base,” said Hans Itburrun, Head of Investments for Banque Audi Suisse. “It was critical that the partner we chose be able to provide a comprehensive global view of equity markets, had a strong foundation of U.S. coverage, and was backed by a strong track record of performance, CFRA easily checked all those boxes and was able to deliver their research to our team through a turnkey, easy-to-use platform.”
"We are delighted to be selected as the exclusive provider of global equity research to Banque Audi Suisse,” says Patricia Wilson, Chief Solutions Officer for CFRA. “This strategic partnership is an important step in our focus on the Swiss market and underscores the value our research and technology offering for private banks and their clients.”
With decades of experience providing unbiased and actionable research, CFRA’s equity research is trusted globally by more than 150,000 financial advisors and relationship managers through its industry-leading MarketScope Advisor platform.
ABOUT CFRA
A global leader in financial intelligence solutions and insights, CFRA blends a proprietary mix of fundamental equity, forensic accounting, fund, public policy/legal, and technical research with data, analytics, and next-gen technology to arm clients with the financial intelligence required to meet their business and investing goals.
Learn more about CFRA Research and their MarketScope Advisor platform.
ABOUT BANQUE AUDI SUISSE
Banque Audi (Suisse) SA was first established in Zurich in 1976. Its headquarters were later relocated to Geneva, close to the city’s historic Old Town and famous lake. Operating under a Swiss banking license and under the supervision of the Swiss Financial Market Supervisory Authority (FINMA), Banque Audi Suisse offers tailor-made Private Banking services to high-net-worth clients, with access to products and foreign exchange markets all over the world.
In the latest study of November 2024 of Zurich University of Applied sciences (ZHAW) on the Best Private Banks in Switzerland in 2024, Banque Audi Suisse has been ranked as the “Best Capitalized Swiss Private Bank 2024”.
Learn more about Banque Audi Suisse.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205074954/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom